GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (OTCPK:YTENQ) » Definitions » Cash-to-Debt

YTENQ (Yield10 Bioscience) Cash-to-Debt : 0.26 (As of Jun. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Yield10 Bioscience Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Yield10 Bioscience's cash to debt ratio for the quarter that ended in Jun. 2024 was 0.26.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Yield10 Bioscience couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Yield10 Bioscience's Cash-to-Debt or its related term are showing as below:

YTENQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.26   Med: 3.76   Max: No Debt
Current: 0.26

During the past 13 years, Yield10 Bioscience's highest Cash to Debt Ratio was No Debt. The lowest was 0.26. And the median was 3.76.

YTENQ's Cash-to-Debt is ranked worse than
71.31% of 251 companies
in the Agriculture industry
Industry Median: 0.76 vs YTENQ: 0.26

Yield10 Bioscience Cash-to-Debt Historical Data

The historical data trend for Yield10 Bioscience's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Yield10 Bioscience Cash-to-Debt Chart

Yield10 Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.60 2.55 4.93 1.59 0.33

Yield10 Bioscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.83 0.33 0.53 0.26

Competitive Comparison of Yield10 Bioscience's Cash-to-Debt

For the Agricultural Inputs subindustry, Yield10 Bioscience's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yield10 Bioscience's Cash-to-Debt Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Yield10 Bioscience's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Yield10 Bioscience's Cash-to-Debt falls into.



Yield10 Bioscience Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Yield10 Bioscience's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Yield10 Bioscience's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yield10 Bioscience  (OTCPK:YTENQ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Yield10 Bioscience Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Yield10 Bioscience's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Yield10 Bioscience Business Description

Traded in Other Exchanges
N/A
Address
19 Presidential Way, Woburn, MA, USA, 01801
Yield10 Bioscience Inc is an agricultural bioscience company. It is leveraging advanced genetics to develop the oilseed Camelina sativa as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and, in the future, PHA bioplastics for use as biodegradable bioplastics.
Executives
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton director 1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser officer: VP Fin and CAO
Lynne H Brum officer: VP Planning and Comms 21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell officer: VP Research & CSO C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey director C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples director, officer: Pres & CEO C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin director 21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully 10 percent owner C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038